Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Seiji Fukamizu is active.

Publication


Featured researches published by Seiji Fukamizu.


European Heart Journal | 2016

Genetic defects in a His-Purkinje system transcription factor, IRX3, cause lethal cardiac arrhythmias

Akiko Koizumi; Tetsuo Sasano; Wataru Kimura; Yoshihiro Miyamoto; Takeshi Aiba; Taisuke Ishikawa; Akihiko Nogami; Seiji Fukamizu; Harumizu Sakurada; Yoshihide Takahashi; Hiroaki Nakamura; Tomoyuki Ishikura; Haruhiko Koseki; Takuro Arimura; Akinori Kimura; Kenzo Hirao; Mitsuaki Isobe; Wataru Shimizu; Naoyuki Miura; Tetsushi Furukawa

AIM Ventricular fibrillation (VF), the main cause of sudden cardiac death (SCD), occurs most frequently in the acute phase of myocardial infarction: a certain fraction of VF, however, develops in an apparently healthy heart, referred as idiopathic VF. The contribution of perturbation in the fast conduction system in the ventricle, the His-Purkinje system, for idiopathic VF has been implicated, but the underlying mechanism remains unknown. Irx3/IRX3 encodes a transcription factor specifically expressed in the His-Purkinje system in the heart. Genetic deletion of Irx3 provides a mouse model of ventricular fast conduction disturbance without anatomical or contraction abnormalities. The aim of this study was to examine the link between perturbed His-Purkinje system and idiopathic VF in Irx3-null mice, and to search for IRX3 genetic defects in idiopathic VF patients in human. METHODS AND RESULTS Telemetry electrocardiogram recording showed that Irx3-deleted mice developed frequent ventricular tachyarrhythmias mostly at night. Ventricular tachyarrhythmias were enhanced by exercise and sympathetic nerve activation. In human, the sequence analysis of IRX3 exons in 130 probands of idiopathic VF without SCN5A mutations revealed two novel IRX3 mutations, 1262G>C (R421P) and 1453C>A (P485T). Ventricular fibrillation associated with physical activities in both probands with IRX3 mutations. In HL-1 cells and neonatal mouse ventricular myocytes, IRX3 transfection up-regulated SCN5A and connexin-40 mRNA, which was attenuated by IRX3 mutations. CONCLUSION IRX3 genetic defects and resultant functional perturbation in the His-Purkinje system are novel genetic risk factors of idiopathic VF, and would improve risk stratification and preventive therapy for SCD in otherwise healthy hearts.


Journal of Arrhythmia | 2015

Evaluation of defibrillation safety and shock reduction in implantable cardioverter-defibrillator patients with increased time to detection: A randomized SANKS study

Mahito Noro; Xin Zhu; Takahito Takagi; Naohiko Sahara; Yuriko Narabayashi; Hikari Hashimoto; Naoshi Ito; Yoshinari Enomoto; Shingo Kujime; Tuyoshi Sakai; Takao Sakata; Noriko Matushita; Seiji Fukamizu; Yoshifumi Okano; Yoshiaki Anami; Tomoyuki Tejima; Kouji Kuroiwa; Takanori Ikeda; Harumizu Sakurada; Kaoru Sugi

The need for ways to minimize the number of implantable cardioverter‐defibrillator (ICD) shocks is increasing owing to the risk of its adverse effects on life expectancy. Studies have shown that a longer detection time for ventricular tachyarrhythmia reduces the safety of therapies, in terms of syncope and mortality, but not substantially in terms of the success rate. We aimed to evaluate the effects of increased number of intervals to detect (NID) VF on the safety of ICD shock therapy and on the reduction of inappropriate shocks.


Circulation | 2007

Association of atrial arrhythmia and sinus node dysfunction in patients with catecholaminergic polymorphic ventricular tachycardia.

Naokata Sumitomo; Harumizu Sakurada; Kazuo Taniguchi; Masaharu Matsumura; Osamu Abe; Michio Miyashita; Hiroshi Kanamaru; Kensuke Karasawa; Mamoru Ayusawa; Seiji Fukamizu; Iori Nagaoka; Minoru Horie; Kensuke Harada; Masayasu Hiraoka


International Journal of Cardiology | 2004

Changes in body surface potential distributions induced by isoproterenol and Na channel blockers in patients with the Brugada syndrome

Naomi Izumida; Yuh Asano; Shouzaburoh Doi; Hiroko Wakimoto; Seiji Fukamizu; Takuro Kimura; Tsuyoshi Ueyama; Harumizu Sakurada; Seiko Kawano; Tohru Sawanobori; Masayasu Hiraoka


Clinical Research in Cardiology | 2017

Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction

Yuya Matsue; Jozine M. ter Maaten; Makoto Suzuki; Sho Torii; Satoshi Yamaguchi; Seiji Fukamizu; Yuichi Ono; Hiroyuki Fujii; Takeshi Kitai; Toshihiko Nishioka; Kaoru Sugi; Yuko Onishi; Makoto Noda; Nobuyuki Kagiyama; Yasuhiro Satoh; Kazuki Yoshida; Peter van der Meer; Kevin Damman; Adriaan A. Voors; Steven R. Goldsmith


International Journal of Cardiology | 2015

Rationale and design of the efficacy of rivaroxaban on renal function in patients with non-valvular atrial fibrillation and chronic kidney disease: The X-NOAC study

Makoto Suzuki; Seiji Fukamizu; Jun-ichi Oyama; Akira Mizukami; Akihiko Matsumura; Yuji Hashimoto; Koichi Node


Japanese Circulation Journal-english Edition | 2003

Significance of Plasma Brain Natriuretic Peptide in Patients with Reversible Left Ventricular Dysfunction takotsubo Cardiomyopathy

Yoshihiro J. Akashi; Yuji Yamamoto; Yuka Mizusawa; Wididjaja Njaman; Tetsuya Katsuno; Yasuhiro Yoshiga; Seiji Fukamizu; Hiroaki Yamaguchi; Jung-cha Oh; Hidetaka Okazaki; Tamotsu Tejima; Harumizu Sakurada; Tomoyuki Kunishima; Masayoshi Sakakibara; Kiyoshi Nakazawa; Fumihiko Miyake


JACC: Clinical Electrophysiology | 2018

Radiofrequency Catheter Ablation of Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy and Apical Aneurysm

Miyako Igarashi; Akihiko Nogami; Kenji Kurosaki; Yuichi Hanaki; Yuki Komatsu; Seiji Fukamizu; Itsuro Morishima; Kazuaki Kaitani; Suguru Nishiuchi; Ahmed Karim Talib; Takeshi Machino; Kenji Kuroki; Hiro Yamasaki; Nobuyuki Murakoshi; Yukio Sekiguchi; Keisuke Kuga; Kazutaka Aonuma


Japanese Circulation Journal-english Edition | 2003

Effects of Quinidine and Aminophyline for Prevention of Ventricular Fibrillation (VF) Induction in Patients with Brugada Syndrome

Hidetaka Okazaki; Yasuhiro Yoshiga; Seiji Fukamizu; Yuka Mizusawa; Wididjaja Njaman; Tetsuya Katsuno; Yoshihiro J. Akashi; Hiroaki Yamaguchi; Jung-cha Oh; Tamotsu Tejima; Harumizu Sakurada; Masayasu Hiraoka


Japanese Circulation Journal-english Edition | 2002

Effects of Sodium Channel Blockers and Bepridil for Maintenance of Sinus Rhythm after Electrical Cardioversion of Recurrent Atrial Fibrillation

Kazuo Itagaki; Hidetaka Okazaki; Seiji Fukamizu; Masaoki Nishimoto; Tetsuya Katsuno; Njaman Widi; Guoxing Wang; Jun-ichi Suzuki; Hiroaki Yamaguchi; Tamotsu Tejima; Osamu Yanase; Harumizu Sakurada; Akihiko Shimizu; Masunori Matsuzaki; Masayasu Hiraoka

Collaboration


Dive into the Seiji Fukamizu's collaboration.

Top Co-Authors

Avatar

Harumizu Sakurada

Tokyo Medical and Dental University

View shared research outputs
Top Co-Authors

Avatar

Masayasu Hiraoka

Tokyo Medical and Dental University

View shared research outputs
Top Co-Authors

Avatar

Hidetaka Okazaki

Tokyo Medical and Dental University

View shared research outputs
Top Co-Authors

Avatar

Hiroaki Yamaguchi

Tokyo Medical and Dental University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Makoto Suzuki

Tokyo Medical and Dental University

View shared research outputs
Researchain Logo
Decentralizing Knowledge